DexCom (NASDAQ:DXCM) Downgraded by StockNews.com to Hold

StockNews.com cut shares of DexCom (NASDAQ:DXCMFree Report) from a buy rating to a hold rating in a report issued on Monday morning.

DXCM has been the subject of a number of other reports. UBS Group upped their price objective on DexCom from $153.00 to $163.00 and gave the stock a buy rating in a research note on Wednesday, April 10th. Citigroup upped their price objective on DexCom from $148.00 to $161.00 and gave the stock a buy rating in a research note on Wednesday, April 3rd. Raymond James upped their price objective on DexCom from $151.00 to $160.00 and gave the stock a strong-buy rating in a research note on Friday, April 26th. Redburn Atlantic initiated coverage on DexCom in a research note on Thursday, May 30th. They set a neutral rating and a $130.00 price objective for the company. Finally, Canaccord Genuity Group upped their price objective on DexCom from $144.00 to $145.00 and gave the stock a buy rating in a research note on Friday, April 26th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus price target of $140.94.

Read Our Latest Stock Report on DXCM

DexCom Price Performance

Shares of NASDAQ DXCM opened at $113.81 on Monday. DexCom has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $45.26 billion, a price-to-earnings ratio of 73.43, a price-to-earnings-growth ratio of 2.85 and a beta of 1.22. The business has a 50 day simple moving average of $128.03 and a 200-day simple moving average of $125.80.

DexCom (NASDAQ:DXCMGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. As a group, equities research analysts expect that DexCom will post 1.78 earnings per share for the current year.

Insider Activity

In other news, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $49,126.35. Following the completion of the sale, the executive vice president now owns 75,877 shares in the company, valued at $8,729,648.85. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Michael Jon Brown sold 629 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the completion of the sale, the executive vice president now owns 68,212 shares in the company, valued at $8,611,765. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the completion of the sale, the executive vice president now owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. Insiders sold a total of 60,837 shares of company stock worth $8,377,125 over the last 90 days. 0.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On DexCom

Hedge funds have recently modified their holdings of the stock. DSM Capital Partners LLC purchased a new stake in shares of DexCom during the fourth quarter valued at $28,000. Crewe Advisors LLC purchased a new stake in shares of DexCom during the first quarter valued at $29,000. Valley National Advisers Inc. lifted its holdings in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. Riverview Trust Co purchased a new stake in shares of DexCom during the first quarter valued at $32,000. Finally, MV Capital Management Inc. lifted its holdings in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

(Get Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Recommended Stories

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.